Basis: Current FMP quote-based enterprise value / matching reported total assets. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Assets ratio is 2.44x as of 2026-10-06T13:46:12.324Z.
Calculation as of: 2026-10-06T13:46:12.324Z.
Quote observation: 2026-10-06T13:45:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: de430a97f2ce1d56e5593aeaf7513a4829955f1ae9df1fe435740c279e59bff8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/ASSETS RATIO
2.44x
SECTOR MEDIAN · HEALTHCARE
1.58x
median of 483 covered companies
CURRENT VS SECTOR MEDIAN
+54.43%
vs the sector median at left
Hemab Therapeutics Holdings, Inc. Common Stock
Market Cap
$1.38B
EV/Assets Ratio
2.44x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
EV/Assets Ratio
1.05x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
EV/Assets Ratio
8.26x
TTM Avg
7.21x
3Y Avg
3.86x
5Y Avg
4.55x
Market Cap
$1.34B
EV/Assets Ratio
9.95x
TTM Avg
6.84x
3Y Avg
3.74x
5Y Avg
3.43x
Market Cap
$1.33B
EV/Assets Ratio
2.97x
TTM Avg
2.97x
3Y Avg
2.48x
5Y Avg
2.48x
Market Cap
$1.47B
EV/Assets Ratio
1.62x
TTM Avg
1.66x
3Y Avg
1.27x
5Y Avg
1.35x
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG) | $1.38B | 2.44x | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | 1.05x | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | 8.26x | 7.21x | 3.86x | 4.55x |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.34B | 9.95x | 6.84x | 3.74x | 3.43x |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | 4.95x | 4.11x | 1.99x | 1.45x |
| ArriVent BioPharma, Inc. (AVBP)vs › | $1.33B | 2.97x | 2.97x | 2.48x | 2.48x |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.47B | 1.62x | 1.66x | 1.27x | 1.35x |
| Kardigan, Inc. (KARD)vs › | $1.29B | 1.27x | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.50B | 3.11x | 3.15x | 2.26x | 2.02x |
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
